Jonathan C.  Javitt net worth and biography

Jonathan Javitt Biography and Net Worth

Chairman of NRx Pharmaceuticals

Dr. Javitt has been a founder of seven successful healthcare IT and biopharma startups with public exits. He has additionally led drug-development engagements for Merck, Allergan, Pharmacia, Novartis, and Pfizer. He was appointed to healthcare leadership roles under Presidents Reagan, George H.W. Bush, Clinton, and George W. Bush. In the latter role he was commissioned by President Bush to Chair the Health Committee of the President’s Information Technology Advisory Committee (PITAC) and to lead the development of Executive Order 13335, establishing the Office of the National Coordinator for Health IT. In the aftermath of 9/11, Dr. Javitt was appointed a Senior Fellow in the National Security Health Policy Center of the Potomac Institute for Policy Studies to focus on biosecurity preparedness and appointed by President Bush to the Office of the Undersecretary of Defense. He is a graduate of Princeton University, Cornell University Medical College, Harvard School of Public Health, the Wills Eye Hospital, and Johns Hopkins School of Medicine. The Harvard Chan School awarded him the Alumnus of Merit award in 2016 and he continues to serve as Adjunct Professor of the Johns Hopkins School of Medicine. Dr. Javitt has published more than 200 scientific works in the areas of health outcomes and Pharmacoeconomics that have been cited by more than 29,000 scientists. In his role as Chief Scientist of NRx Pharmaceuticals he continues to lead NRx on Scientific matters to advance and expand our pipeline of lifesaving medicines.

What is Jonathan C. Javitt's net worth?

The estimated net worth of Jonathan C. Javitt is at least $300.87 thousand as of December 17th, 2024. Javitt owns 84,634 shares of NRx Pharmaceuticals stock worth more than $300,874 as of August 25th. This net worth approximation does not reflect any other investments that Javitt may own. Learn More about Jonathan C. Javitt's net worth.

How do I contact Jonathan C. Javitt?

The corporate mailing address for Javitt and other NRx Pharmaceuticals executives is 2645 N. Federal Highway Suite 230, Delray Beach FL, 33483. NRx Pharmaceuticals can also be reached via phone at (484) 254-6134 and via email at [email protected]. Learn More on Jonathan C. Javitt's contact information.

Has Jonathan C. Javitt been buying or selling shares of NRx Pharmaceuticals?

Jonathan C. Javitt has not been actively trading shares of NRx Pharmaceuticals during the last ninety days. Most recently, on Tuesday, December 17th, Jonathan C. Javitt bought 40,000 shares of NRx Pharmaceuticals stock. The stock was acquired at an average cost of $1.17 per share, with a total value of $46,800.00. Following the completion of the transaction, the chairman now directly owns 84,634 shares of the company's stock, valued at $99,021.78. Learn More on Jonathan C. Javitt's trading history.

Who are NRx Pharmaceuticals' active insiders?

NRx Pharmaceuticals' insider roster includes Robert Besthof (Insider), Alessandra Daigneault (General Counsel), and Jonathan Javitt (Chairman). Learn More on NRx Pharmaceuticals' active insiders.

Jonathan C. Javitt Insider Trading History at NRx Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/17/2024Buy40,000$1.17$46,800.0084,634View SEC Filing Icon  
8/22/2023Buy20,000$3.20$64,000.0034,633View SEC Filing Icon  
12/7/2022Sell40,000$10.00$400,000.001,289,999View SEC Filing Icon  
6/1/2022Buy1,000$5,800.00$5,800,000.001,463View SEC Filing Icon  
See Full Table

Jonathan C. Javitt Buying and Selling Activity at NRx Pharmaceuticals

This chart shows Jonathan C Javitt's buying and selling at NRx Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

NRx Pharmaceuticals Company Overview

NRx Pharmaceuticals logo
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.
Read More

Today's Range

Now: $3.58
Low: $3.43
High: $3.65

50 Day Range

MA: $3.74
Low: $3.05
High: $4.48

2 Week Range

Now: $3.58
Low: $1.62
High: $5.05

Volume

421,672 shs

Average Volume

1,136,473 shs

Market Capitalization

$154.80 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.18